Oncopeptides AB (publ) (FRA:OND)

Market Cap	34.62M +10.4%
Revenue (ttm)	6.57M +124.7%
Net Income	-23.06M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,200
Average Volume	4,050
Open	0.1312
Previous Close	0.1290
Day's Range	0.1312 - 0.1334
52-Week Range	0.1166 - 0.5960
Beta	n/a
RSI	31.79
Earnings Date	Apr 28, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 75
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OND

Financial Performance

In 2025, Oncopeptides AB's revenue was 71.12 million, an increase of 124.72% compared to the previous year's 31.65 million. Losses were -249.59 million, -12.31% less than in 2024.

Financial numbers in SEK